3 results
- To compare the primary pharmacokinetic parameters AUC0-last, AUC0-*, and Cmax of MK-8228 after single dose administration of one tablet of 480 mg MK-8228 (test) and two tablets of 240 mg MK-8228 (reference) under fasting conditions.- To compareā¦
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
The primary objective of this study is to compare in a non-inferiority design the safety and efficacy of iwFR (or comparable resting diastolic indices)-guided complete revascularization after (within 1-45 days) with iwFR (or comparable restingā¦